DekaBank Deutsche Girozentrale Raises Stock Position in DexCom, Inc. $DXCM

DekaBank Deutsche Girozentrale raised its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 1.5% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 850,305 shares of the medical device company’s stock after buying an additional 12,685 shares during the period. DekaBank Deutsche Girozentrale’s holdings in DexCom were worth $73,715,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of DXCM. Golden State Wealth Management LLC grew its holdings in shares of DexCom by 211.2% in the first quarter. Golden State Wealth Management LLC now owns 389 shares of the medical device company’s stock worth $27,000 after acquiring an additional 264 shares during the period. Zions Bancorporation National Association UT bought a new position in DexCom in the first quarter valued at about $27,000. Anderson Financial Strategies LLC purchased a new position in DexCom in the first quarter worth about $37,000. Alpine Bank Wealth Management bought a new stake in shares of DexCom during the 1st quarter valued at about $40,000. Finally, Private Trust Co. NA grew its stake in shares of DexCom by 99.4% during the 1st quarter. Private Trust Co. NA now owns 672 shares of the medical device company’s stock valued at $46,000 after purchasing an additional 335 shares during the period. 97.75% of the stock is owned by institutional investors.

DexCom Stock Performance

Shares of NASDAQ DXCM opened at $69.75 on Wednesday. The stock has a market cap of $27.35 billion, a PE ratio of 48.44, a price-to-earnings-growth ratio of 1.44 and a beta of 1.47. DexCom, Inc. has a 1 year low of $57.52 and a 1 year high of $93.25. The firm has a fifty day moving average price of $72.95 and a 200-day moving average price of $77.70. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.52 and a quick ratio of 1.35.

DexCom (NASDAQ:DXCM) last released its earnings results on Wednesday, July 30th. The medical device company reported $0.48 earnings per share for the quarter, beating analysts’ consensus estimates of $0.45 by $0.03. DexCom had a net margin of 13.29% and a return on equity of 30.41%. The company had revenue of $1.16 billion for the quarter, compared to analysts’ expectations of $1.13 billion. During the same quarter in the previous year, the company earned $0.43 EPS. DexCom’s revenue for the quarter was up 15.2% on a year-over-year basis. DexCom has set its FY 2025 guidance at EPS. Equities analysts anticipate that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, EVP Michael Jon Brown sold 500 shares of the business’s stock in a transaction that occurred on Friday, August 15th. The stock was sold at an average price of $80.29, for a total value of $40,145.00. Following the transaction, the executive vice president directly owned 94,102 shares of the company’s stock, valued at approximately $7,555,449.58. The trade was a 0.53% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Sadie Stern sold 1,466 shares of the company’s stock in a transaction that occurred on Thursday, September 4th. The stock was sold at an average price of $80.00, for a total value of $117,280.00. Following the completion of the transaction, the executive vice president owned 105,223 shares of the company’s stock, valued at $8,417,840. The trade was a 1.37% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 6,849 shares of company stock worth $564,733. 0.32% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the stock. Barclays increased their price objective on shares of DexCom from $93.00 to $98.00 and gave the stock an “equal weight” rating in a research note on Wednesday, July 30th. Stifel Nicolaus began coverage on shares of DexCom in a research report on Tuesday. They issued a “buy” rating and a $85.00 price target on the stock. Canaccord Genuity Group reissued a “buy” rating and set a $106.00 price objective on shares of DexCom in a research report on Monday, September 29th. The Goldman Sachs Group decreased their target price on DexCom from $104.00 to $89.00 and set a “buy” rating on the stock in a report on Wednesday, October 1st. Finally, Truist Financial lowered their target price on DexCom from $102.00 to $94.00 and set a “buy” rating on the stock in a research report on Wednesday, October 15th. Three analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and six have given a Hold rating to the company. According to MarketBeat, DexCom presently has a consensus rating of “Moderate Buy” and an average price target of $96.40.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.